The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

The American Cancer Society has released its latest report on cancer in the United States, revealing both encouraging and concerning trends.

Virginia G. Kaklamani, MD, DSc, discusses findings from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan.

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

Scientists have made 'exciting,' patient-friendly advances in developing a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. This emerging technology holds ...

The American Cancer Society (ACS) today released Cancer Statistics, 2025, the organization's annual report on cancer facts and trends. The new findings show the cancer mortality rate declined by 34% ...

Datroway has been approved for unresectable or metastatic HR+, HER2- breast cancer after endocrine therapy and chemotherapy.

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for ...

And, in fact, this study showed that the additional palbociclib to this kind of treatment was able to significantly prolong PFS from the start of the maintenance treatment with a benefit in terms of ...

The American Cancer Society is asking North Dakota State lawmakers to pass legislation that would require insurance companies to cover diagnostic testing for people who need it when doctors find ...

A new report shows young women are nearly twice as likely as young men to be diagnosed with cancer. Cancer rates among men generally declined in the U.S. early this century before leveling out. But ...

It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...